tebapivat
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 20, 2024 (NCT06745271)
Timeline
Indications
Mechanism of action
- Pyruvate kinase isozymes R/LACTIVATOR
PKLR activator
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c2nc(Cc3cc[nH]n3)sc2c2cnn(Cc3cccc(N)n3)c(=O)c21- Mol. weight
- 392.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314542 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06924970 | Phase 2 | May 1, 2025 | Agios Pharmaceuticals, Inc. |
| NCT06745271 | Phase 1 | Dec 20, 2024 | Agios Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1